Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 1/20 | 1.00 |
| ▸ | LIMK2 | P53671 | 1/20 | 1.00 |
| ▸ | BCL2 | P10415 | 3/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | PKLR | P30613 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Damnacanthal SCHEMBL29356591 | 1.00 | MAPT (1.00) | MAPTALDH1A1LCKGLATHRB | |
| SCHEMBL16226525 | 0.89 | ALDH1A1 (0.80) | MAPTALDH1A1LCKGLATHRB | |
| SCHEMBL16225884 | 0.84 | MAPT (0.72) | MAPTALDH1A1LCKGLATHRB | |
| SCHEMBL8341400 | 0.82 | MAPT (0.69) | MAPTALDH1A1LCKGLATHRB | |
| SCHEMBL16227041 | 0.81 | MAPT (0.68) | MAPTALDH1A1LCKGLATHRB | |
| SCHEMBL30407933 | 0.80 | BCL2 (0.67) | MAPTALDH1A1LCKGLATHRB | |
| SCHEMBL16227182 | 0.80 | BCL2 (0.67) | MAPTALDH1A1LCKGLATHRB | |
| SCHEMBL1149730 | 0.79 | MAPT (0.66) | MAPTALDH1A1LCKGLATHRB | |
| SCHEMBL18601895 | 0.79 | MAPT (0.65) | MAPTALDH1A1LCKGLATHRB | |
| SCHEMBL29066464 | 0.78 | MAPT (0.63) | MAPTALDH1A1LCKGLATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360129-A1 | COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS | UNIV YALE (US) | 2025-11-27 | — | — | US | claimed |
| EP-3250192-B1 | COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS | UNIV YALE (US) | 2025-10-08 | — | — | EP | claimed |
| US-20250122295-A1 | METHOD OF TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIA | CSL LIMITED (AU) | 2025-04-17 | — | — | US | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2024111000-A1 | AN ANTI-CANCER COMPOSITION OF HERBAL EXTRACTS AND ITS METHOD OF PREPARATION THEREOF | M/S VALYOU PRODUCTS PRIVATE LIMITED (IN) | 2024-05-30 | — | — | WO | claimed |
| US-20230148436-A2 | NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOF | SHENZHEN UNIVERSITY (CN) | 2023-05-11 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| US-20230036788-A1 | COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS | UNIV YALE (US) | 2023-02-02 | — | — | US | claimed |
| CN-115245533-A | Application of south mountain flower root extract in pulmonary fibrosis treatment | 中国医学科学院药物研究所 | 2022-10-28 | — | — | CN | claimed |
| CN-115192726-A | Synthesis of immune agonist targeting compound and application thereof | 深圳大学 | 2022-10-18 | — | — | CN | claimed |
| JP-2005533604-A | — | — | 2005-11-10 | — | — | JP | claimed |
| US-20050203612-A1 | Luminal prostheses which allow for programmed and controlled delivery of mycophenolic acid or derivatives with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis and hyperplasia | AVANTEC VASCULAR CORPORATION (US) | 2005-09-15 | — | — | US | claimed |
| EP-1539041-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | Avantec Vascular Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2005051229-A2 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | WO | claimed |
| US-20050125054-A1 | Devices delivering therapeutic agents and methods regarding the same | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | US | claimed |
| WO-2004010900-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2004-02-05 | — | — | WO | claimed |
| US-6610483-B1 | Methods for identifying cellular responses attributable to signaling molecule inhibition and inhibitors thereof | PRINCETON UNIVERSITY | 2003-08-26 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1196626-A2 | METHODS FOR IDENTIFYING INHIBITORS OF SIGNALING MOLECULES | Princeton University (US) | 2002-04-17 | — | — | EP | claimed |
| WO-2001007659-A2 | METHODS FOR IDENTIFYING INHIBITORS OF SIGNALING MOLECULES | PRINCETON UNIVERSITY (US) | 2001-02-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148436-A2 | NOVEL SMALL MOLECULE IMMUNE AGONISTS AND IMMUNE TARGETING COMPOUNDS AND APPLICATION THEREOF | IFNG, IFNAR1, STING1 | MAPT 4751/4885ALDH1A1 4334/4885LCK 383/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | MAPT 3926/4885ALDH1A1 2722/4885LCK 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.